Investment in Bio Industry
OCI aims to become a leading global player in bio-business with the acquisition and development (A&D) of specialized leading technologies
Background of bio
business launch
- A technology-intensive growth sector with higher added value than traditional industries
- A sector that can use OCI’s accumulated technology and experience in fine chemical engineering
- Overcoming the limitations of volatility in the chemical business and securing stable sales and profits
Vision and Strategy
OCI’s bio business roadmap
Major investments
| Company Name | Main Business | Investment Amount | Results |
| Bukwang Pharmaceutical (Korea) | Integrated pharmaceutical company | KRW 146.1 billion | SOL-804 (prostate cancer medicine), clinical trial phase 1 completed |
| SN Bio Science (Korea) | Nanoparticle drug delivery system | KRW 5 billion | SNB-101(pancreatic cancer drug) Clinical trial phase 1, USA, Korea |
| Panolos Bioscience (Korea) | Multi-specific recombinant protein | KRW 5 billion | PB101 (new cancer therapy candidates) The pre-clinical phase started. |
| Adicet* (USA) | Immunotherapy using homogeneous treatment method | USD 7.8 million | CAR-T** therapy of lymphoma; interim results of the clinical trial phase 1 announced |
| Nucleix (Israel) | Early diagnosis of cancer; Liquid Biopsy | USD 5.5 million | Diagnostic kit to test bladder cancer, U.S. FDA approval underway R&D of lung cancer diagnostic kit |
| Synergy Fund (Korea) | Invest in bio ventures for new drugs and medical devices | KRW 3 billion |
* Adicet : After merger with resTORbio, a NASDAQ-listed bio company, listed on NASDAQ in September 2020 under the company name Adicet Bio
** CAR-T : Allogeneic chimeric antigen receptor T cells
